Back to Actions

Bill History in the Congressional Record

Page numbers for legislative actions on this bill link to the Congressional Record. Learn more about the History of Bills and Resolutions.


From the Congressional Record, Volume 165 (2019)









H.R. 938 — A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes; to the Committee on Energy and Commerce.

By Mr. SCHRADER (for himself and Mr. Carter of Georgia), H1341 [31JA]
Cosponsors added, H2797 [25MR], H2828 [26MR], H2887 [27MR], H2923 [29MR], H2987 [2AP], H3130 [8AP], H3259 [10AP], H3305 [29AP], H3406 [1MY]
Reported (H. Rept. 116–46), H3438 [2MY]



From the Congressional Record, Volume 166 (2020)

H.R. 938 — A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes; to the Committee on Energy and Commerce.
By Mr. SCHRADER (for himself and Mr. Carter of Georgia), H1341 [31JA]
Cosponsors added, H2797 [25MR], H2828 [26MR], H2887 [27MR], H2923 [29MR], H2987 [2AP], H3130 [8AP], H3259 [10AP], H3305 [29AP], H3406 [1MY]
Reported (H. Rept. 116–46), H3438 [2MY]